bell
The current prices are delayed by 15 mins, login to check live prices.
Biocon Ltd share price logo

Biocon Ltd

(BIOCON)

₹329.551.91%

as on 04:01PM, 23 Dec 2024

Overview
News
Financials
Q2 2024 Results
Technicals
F&O

Biocon Ltd Analyst Rating

based on 18 analysts

HOLD

55.56%

Buy

5.56%

Hold

38.89%

Sell

Based on 18 analysts offering long term price targets for Biocon Ltd. An average target of ₹342.83

Source: S&P Global Market Intelligence

Biocon Ltd Share analysis

Biocon Ltd price forecast by 18 analysts

Upside of2.05%

High

₹460

Target

₹342.83

Low

₹235

Biocon Ltd target price ₹342.83, a slight upside of 2.05% compared to current price of ₹329.55. According to 18 analysts rating.

Source: S&P Global Market Intelligence

Biocon Ltd Performance

  • Day's Low

    Day's High

    ₹329
    Day's Price Range
    ₹339.6
  • 52 Week's Low

    52 Week's High

    ₹239.3
    52-Week Price Range
    ₹395.8
1 Month Return-0.12 %
3 Month Return-9.29 %
1 Year Return+ 34.03 %
Previous Close₹335.95
Open₹338.45
Volume20.08L
Upper Circuit-
Lower Circuit-
Market Cap₹40,334.16Cr

Biocon Ltd Key Statistics

P/E Ratio29.12
PEG Ratio3.71
Market Cap₹40,334.16 Cr
P/B Ratio2.91
EPS10.81
Dividend Yield0.19
SectorPharmaceuticals
ROE0.97

Biocon Ltd Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
HOLD₹40,334.16 Cr3.52%0.58₹1,297 Cr₹14,755 Cr
HOLD₹1,55,212.84 Cr44.67%0.50₹1,600 Cr₹7,845 Cr
BUY₹1,16,318.47 Cr53.62%0.67₹1,656 Cr₹10,727 Cr
HOLD₹29,198.95 Cr-0.52%0.50₹772 Cr₹5,664 Cr
BUY₹1,18,884.82 Cr42.93%0.50₹4,155 Cr₹25,774 Cr

About Biocon Ltd

Biocon Ltd is a biopharmaceutical company founded in 1978 by Kiran Mazumdar-Shaw. It is headquartered in Bangalore, India and is one of the top biopharma companies in the world. The company operates in four core areas - biopharmaceuticals, biologics, research services, and clinical research. Biocon's biopharmaceuticals business focuses on biologics and biosimilars, while its biologics business focuses on the discovery, development and commercialization of novel biologics. Its research services include contract research and manufacturing services, while its clinical research business focuses on clinical trials and clinical data management.

Biocon's top products include insulin, monoclonal antibodies, enzymes, and vaccines. Its popular brands include Insugen, Insupen, and Insugen Plus. The company has a strong presence in the Indian market and is expanding its reach to other countries. Biocon has also established its presence in the US, Europe, and Japan.

Share Price: ₹329.55 per share as on 23 Dec, 2024 04:01 PM
Market Capitalisation: ₹40,334.16Cr as of today
Revenue: ₹3,545.00Cr as on September 2024 (Q3 24)
Net Profit: ₹27.10Cr as on September 2024 (Q3 24)
Listing date: 07 Apr, 2004
Chairperson Name: Kiran Mazumdar Shaw
OrganisationBiocon Ltd
HeadquartersBangalore
IndustryPharmaceuticals
E-voting on sharesClick here to vote

Key events for Biocon Ltd

  • Biocon Biologics Gains EMA Approval for YESINTEK - 16 Dec, 2024

    Biocon Biologics' YESINTEK, a Ustekinumab biosimilar, received a positive recommendation from the European Medicines Agency, enhancing Biocon's position in the biosimilar market.
  • Kiran Mazumdar-Shaw Receives Jamsetji Tata Award - 14 Dec, 2024

    Kiran Mazumdar-Shaw, founder of Biocon Limited, was awarded the Jamsetji Tata Award for her pioneering contributions to the biosciences movement in India since 1978.
  • Biocon Sells Stake in Syngene, Receives IP Recognition - 11 Dec, 2024

    Biocon sold 80 lakh shares of Syngene International for Rs 686 crore, lowering its stake to 52.46%. Additionally, Biocon Biologics was recognized as an Asia IP Elite for 2024, continuing its legacy of excellence in intellectual property.
  • Biocon Divests Stake in Syngene International - 10 Dec, 2024

    Biocon Ltd announced plans to divest a 2% stake in Syngene International, successfully selling 80 lakh shares for Rs 686 crore, reducing its ownership to 52.46%. This strategic move reflects Biocon's ongoing adjustments in its investment portfolio.
  • Biocon Faces Loss Amid USFDA Inspection Report - 09 Dec, 2024

    Biocon announced a consolidated net loss of Rs 16 crore in Q2 FY25, alongside receiving a Voluntary Action Indicated status from the USFDA for its Bengaluru API facility.
  • Biocon Electric Launches New Switches Nationwide - 05 Dec, 2024

    Biocon Electric has launched a new range of high-quality switches to meet growing demand in India. The company aims to expand its presence from 14 to 20 states by next year, focusing on providing affordable, innovative electrical solutions for residential and commercial spaces.
  • Biocon Secures FDA Approval for Yesintek Biosimilar - 02 Dec, 2024

    Biocon Biologics' Yesintek, a biosimilar to Johnson & Johnson's Stelara, received USFDA approval, boosting Biocon's market position and stock performance. The approval is expected to drive growth in international markets.
  • Biocon Biologics Secures FDA Approval for YESINTEK - 01 Dec, 2024

    Biocon Biologics has received US FDA approval for YESINTEK, a biosimilar for treating Crohn's disease and other autoimmune conditions, with commercialization planned by February 2025.
  • Biocon Advances Diabetes Care Project, Analyst Recommends Buy - 28 Nov, 2024

    Biocon Biologics reported progress in its diabetes care initiative in Ethiopia. An analyst recommends buying Biocon stock with a target price of ₹320-325.
  • Biocon Ltd Shows Bullish Momentum Amid Market Interest - 26 Nov, 2024

    Biocon Ltd traded between Rs 336.05 and Rs 355.45, nearing its 52-week high. Analysts recommend a buy above Rs 355.45, targeting Rs 360.00, while maintaining a positive outlook on growth potential.
  • Geojit Financial Services Recommends Accumulate on Biocon - 21 Nov, 2024

    Geojit Financial Services has reiterated an 'Accumulate' rating on Biocon Ltd with a target price of Rs. 376. The company's revenue grew 3.7% YoY, driven by strong biosimilar sales, despite a decline in the generics segment. Biocon's growth prospects are bolstered by a VAI classification for its Biologics Park and early signs of recovery in its research services arm, Syngene.
  • Biocon Biologics Plans to Reduce Debt by $300 Million - 19 Nov, 2024

    Biocon Biologics aims to reduce $300 million in acquisition debt within a year, following a recent refinancing of $1.1 billion. The company anticipates growth in its biosimilar and insulin markets, with plans to double insulin capacity in Malaysia. A positive USFDA inspection outcome could facilitate the launch of a new biosimilar in the US.

Insights on Biocon Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 5.90% to 5.93% in Sep 2024 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Vimta Labs Ltd has given 142.4% return, outperforming this stock by 152.7%

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 60.64% of holdings in Sep 2024 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Vimta Labs Ltd has given 137.3% return, outperforming this stock by 103.2%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 4.59K Cr → 3.64K Cr (in ₹), with an average decrease of 20.7% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 years, BIOCON stock has moved down by -10.3%

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 18.89% to 18.75% in Sep 2024 quarter

  • imgNEGATIVE IMPACT

    MF Holding Down

    img

    Mutual Funds have decreased holdings from 8.69% to 7.97% in Sep 2024 quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 659.7 Cr → -16.0 Cr (in ₹), with an average decrease of 102.4% per quarter

Biocon Ltd Financials

Value in ₹ crore
DetailsQ'3 23Q'4 23Q'1 24Q'2 24Q'3 24
Revenue₹3,392.60Cr (-)₹3,953.70Cr (↑16.54%)₹3,917.10Cr (↓0.93%)₹3,376.10Cr (↓13.81%)₹3,545.00Cr (↑5.00%)
Net Income₹172.70Cr (-)₹753.30Cr (↑336.19%)₹222.90Cr (↓70.41%)₹861.80Cr (↑286.63%)₹27.10Cr (↓96.86%)
Net Profit Margin5.09% (-)19.05% (↑274.26%)5.69% (↓70.13%)25.53% (↑348.68%)0.76% (↓97.02%)
Value in ₹ crore
Details2021202220232024
Total Assets₹8,622.70Cr (-)₹8,908.60Cr (↑3.32%)₹13,052.00Cr (↑46.51%)₹13,797.80Cr (↑5.71%)
Total Liabilities₹715.60Cr (-)₹815.70Cr (↑13.99%)₹2,136.00Cr (↑161.86%)₹2,885.50Cr (↑35.09%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹387.10Cr (-)₹571.30Cr (↑47.58%)₹47.60Cr (↓91.67%)₹219.30Cr (↑360.71%)-₹123.20Cr (↓156.18%)

Index Inclusions

Nifty Midcap 150

₹21,076.15

0.12 (25.55%)

Nifty Midcap 100

₹57,092.90

0.33 (186.15%)

Nifty Healthcare

₹14,469.55

-0.04 (-5.35%)

BSE 200

₹10,966.08

0.55 (60.22%)

Nifty 200

₹13,449.75

0.57 (75.85%)

NIFTY PHARMA

₹22,572.05

0.31 (70.2%)

BSE 500

₹35,231.44

0.43 (149.19%)

BSE Mid-Cap

₹46,274.31

0.1 (47.81%)

S&P BSE 400 MidSmallCap

₹12,094.45

-0.06 (-7.27%)

S&P BSE 150 MidCap

₹15,882.43

0.12 (19.54%)

Nifty LargeMidcap 250

₹15,722.90

0.36 (56.9%)

BSE Healthcare

₹44,078.53

-0.04 (-16.93%)

Nifty 500

₹22,412.30

0.42 (92.9%)

S&P BSE 250 LargeMidCap

₹10,406.99

0.52 (53.71%)

Nifty MidSmallcap 400

₹19,883.95

-0.08 (-15.45%)

S&P BSE AllCap

₹10,471.31

0.68 (71.07%)

Biocon Ltd Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
60.64%
0.00
Foreign Institutions
5.93%
0.47
Mutual Funds
7.97%
-8.31
Retail Investors
18.75%
-0.73
Others
6.72%
14.14

Biocon Ltd Key Indicators

Details20202021202220232024
Return On Equity %4.163.631.08-0.140.97
Details20202021202220232024
Return On Assets %8.958.597.283.557.41
Details20202021202220232024
Book Value Per Share (₹)55.8763.5570.23148.81164.77
Details20202021202220232024
Earning Per Share (₹)7.267.056.435.3610.81

Biocon Ltd Valuation

Biocon Ltd in the last 5 years

  • Overview

  • Trends

Lowest (24.48x)

March 19, 2024

Today (29.12x)

December 19, 2024

Industry (56.23x)

December 19, 2024

Highest (118.86x)

September 27, 2018

LowHigh

Biocon Ltd Earnings and Dividends

  • Biocon Ltd Earnings Results

    Biocon Ltd’s net profit fell -112.74% since last year same period to ₹-16Cr in the Q2 2024-2025. On a quarterly growth basis, Biocon Ltd has generated -102.43% fall in its net profits since last 3-months.

    Read More about Earnings Results
  • Biocon Ltd Dividends May,2024

    In the quarter ending March 2024, Biocon Ltd has declared dividend of ₹0.50 - translating a dividend yield of 0.61%.

    Read More about Dividends

Biocon Ltd Technicals Summary

Bearish

Neutral

Bullish

Bearish

Biocon Ltd is currently in a Bearish trading position according to technical analysis indicators.

FAQs on Biocon Ltd

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Biocon Ltd shares.

Biocon Ltd (BIOCON) share price today is ₹329.55

Biocon Ltd is listed on NSE

Biocon Ltd is listed on BSE

  • Today’s highest price of Biocon Ltd is ₹339.6.
  • Today’s lowest price of Biocon Ltd is ₹329.

PE Ratio of Biocon Ltd is 29.12

PE ratio = Biocon Ltd Market price per share / Biocon Ltd Earnings per share

Today’s traded volume of Biocon Ltd(BIOCON) is 20.08L.

Today’s market capitalisation of Biocon Ltd(BIOCON) is ₹40334.16Cr.

Biocon Ltd(BIOCONPrice
52 Week High
₹395.8
52 Week Low
₹239.3

Biocon Ltd(BIOCON) share price is ₹329.55. It is down -16.74% from its 52 Week High price of ₹395.8

Biocon Ltd(BIOCON) share price is ₹329.55. It is up 37.71% from its 52 Week Low price of ₹239.3

Biocon Ltd(BIOCONReturns
1 Day Returns
-6.4%
1 Month Returns
-0.12%
3 Month Returns
-9.29%
1 Year Returns
34.03%